NeuroVia Appoints Daniel Bradbury and Edward Kaye to its Board of Directors
Cambridge, MA, September 28, 2017 – NeuroVia Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, today announced the expansion of its Board of Directors with the addition of Daniel Bradbury, former CEO of Amylin Pharmaceuticals, who will serve as Chairman of the Board, and Edward Kaye, former CEO and CMO of Sarepta Therapeutics, who will join as an independent member.
“The addition of these two seasoned industry executives to the Board of Directors is a testament to the potential of NeuroVia and its promising program for X-ALD patients,” said Jason Hafler, member of NeuroVia’s Board of Directors and Senior Director of Investments at Sanofi-Genzyme BioVentures. “Dan’s years of experience in the global life science industry will undoubtedly contribute to NeuroVia as the company moves forward in the clinic and continues to work to reach its goal of addressing unmet medical needs for rare neurological diseases such as X-ALD. In addition, Ed’s pertinent background as an X-ALD physician as well as an experienced drug developer will be a valuable resource to the company.”
“NeuroVia is built on a solid scientific foundation and has developed a promising therapeutic strategy for treating rare neurological diseases,” said Daniel Bradbury. “I am particularly excited to lead the Board and work with both them and the leadership team to bring new therapies to patients with limited treatment options.”
“I am eager to contribute to the advancement of the company and support the realization of the full potential inherent in the company’s pipeline,” added Edward Kaye. “As someone committed to bringing innovative and effective therapies to patients with limited or no options, it is an honor to contribute to the advancement of this company for the treatment of X-ALD.”
Mr. Daniel Bradbury has over 30 years of experience leading global, fast-growing life sciences companies. Since 2012, Mr. Bradbury has been a managing member of BioBrit, LLC, a life sciences consulting and investment firm. Mr. Bradbury served as the president, chief executive officer and as a director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, California, focused on metabolic diseases, from March 2007 until it was acquired by the Bristol-Myers Squibb Company in August 2012. Prior to being named president and chief executive officer, Mr. Bradbury held positions of increasing responsibility at Amylin since 1994, including president (2006 – 2007), chief operating officer (2003 – 2006) and executive vice president (2000 – 2003). Mr. Bradbury currently serves as a director of Corcept Therapeutics, Inc., Geron Corporation and Intercept Pharmaceuticals, Inc., all of which are NASDAQ-listed biopharmaceutical companies, and Biocon Limited, a biopharmaceutical company traded on the National Stock Exchange of India. He is an advisory board member of Patricia Industries (a part of Investor AB) and is a member of the advisory committee of BioMed Ventures. Mr. Bradbury also serves on the University of California San Diego's Rady School of Management's Advisory Council and the Keck Graduate Institute's Board of Trustees. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Dr. Edward Kaye joins NeuroVia’s Board of Directors having most recently served at Sarepta as the Chief Executive Officer as well as the Chief Medical Officer, from 2011 to 2017. Dr. Kaye continues to serve as a board member and Special Regulatory and Scientific Advisor to the company. Prior to joining Sarepta, Dr. Kaye was employed by Genzyme Corporation for ten years, holding various senior management positions, the most recent of which was Group Vice President of Clinical Development, in which he supervised clinical research in lysosomal storage disease programs and genetic neurological disorders. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University of Pennsylvania School of Medicine. Dr. Kaye serves as a Neurological Consultant at the Children’s Hospital of Boston and is on the editorial boards of a number of medical journals. He is also a member of several scientific advisory boards, including United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and Prize4Life. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University.
X-linked adrenoleukodystrophy (X-ALD) is a rare, genetic disorder affecting 1 in 17,000 people worldwide that causes adrenal gland dysfunction and loss of the protective sheath that surrounds nerve fibers in the central nervous system. The childhood version progresses quickly and results in a severe neurodegenerative phenotype which is often fatal within three to five years after onset of initial symptoms. The adult-onset version is characterized by numbness in the legs leading to difficulty or inability to walk and urinary and bowel incontinence. With no curative treatment currently available, there exists an unmet medical need for a therapeutic benefit for X-ALD patients.
NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.